Background and purpose: There are a few retrospective subgroup analyses or registries of large-vessel (≥3.5 mm) stenting. We investigated clinical outcomes of patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI) with drug-eluting stents (DES) and bare-metal stents (BMS) in large coronary vessels. Methods and subjects: Of 1100 STEMI patients registered in the Ibaraki Cardiovascular Assessment Study (ICAS) multicenter registry from April 2007 to June 2012 who underwent PCI, we enrolled 454 patients (65.8 ± 12.7 years old, 81% male) with ≥3.5-mm stents. We excluded 53 patients with cardiogenic shock or left main trunk lesions. The remaining 401 patients were divided into Group-D, PCI with DES (n = 184), and Group-B, PCI with BMS (n = 217). Propensity score analysis matched 1:1 according to treatment with DES (n = 101) or with BMS (n = 101). We evaluated major adverse cardiac and cerebrovascular events (MACCE) and incidence of stent thrombosis (ST). MACCE was defined as all-cause death, myocardial infarction (MI), target-vessel revascularization (TVR), or cerebrovascular accident (CVA). Essential results: During a mean follow-up period of 526 days, all-cause death, MI, CVA, MACCE, and ST were not significantly different in Group-D versus Group-B (all-cause death: 4.35% vs. 4.61%, p = 0.90; MI: 0% vs. 0%; CVA: 2.72% vs. 3.23%, p = 0.76; MACCE: 15.2% vs. 20.3%, p = 0.19; and ST: 0.0% vs. 1.38%, p = 0.11). After adjusting for age, insulin use, multivessel disease, intra-aortic balloon pump use, culprit lesions, and estimated glomerular filtration rate <60 ml/min/1.73 m 2 , MACCE was not significantly different between the groups (odds ratio: 0.69; 95% CI: 0.40-1.23; p = 0.21). However, TVR was significantly lower in Group-D than Group-B in Kaplan-Meier analysis (p = 0.048) after propensity score matching. Principal conclusion: There was no advantage to using a DES in large vessels for preventing a hard endpoint, whereas DES use resulted in a significant reduction in TVR in the patients with STEMI in this registry.
Introduction
Percutaneous coronary intervention (PCI) is the ideal reperfusion tactic for patients with ST-segment elevation myocardial infarction (STEMI) [1] [2] [3] . Drug-eluting stents (DES) have reduced the rate of restenosis as compared with bare-metal stents (BMS). However, for patients with stenoses in large coronary arteries, the benefit of the use of DES has been considered uncertain. "Bigger is better" was the catchphrase in the BMS era. Elezi et al. and others reported that patients with small vessels present a higher risk for an adverse outcome after coronary stent placement because of a higher incidence of restenosis [4, 5] . In contrast, no significant reduction in the rate of target-vessel revascularization (TVR) was found in the BASKET sub-study among patients with stenoses in http://dx.doi.org/10.1016/j.jjcc.2014.02.020 0914-5087/© 2014 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved. large coronary arteries who received DES and those who received BMS [6, 7] . Kaiser et al. reported that in patients requiring stenting of large coronary arteries (≥3.0 mm), there were no significant differences in the rates of death or myocardial infarction (MI) among patients with sirolimus-eluting stents (SES), everolimus-eluting stents (EES), and BMS [8] . In contrast, in small-vessel stenting, the particular benefit of DES has been shown repeatedly [9] [10] [11] [12] [13] [14] [15] . Furthermore, the risk of late stent thrombosis has been shown for DES, as premature discontinuation of dual antiplatelet therapy is a major risk factor [16, 17] . There have been a few retrospective subgroup analyses or registries of large vessel stenting (≥3.5 mm) [18, 19] . Although it is difficult to know the patient's background in the setting of acute coronary syndrome, the interventional cardiologist nevertheless needs to choose the stent immediately. It is unclear whether DES or BMS should be used in large vessels (defined as those with a diameter of ≥3.5 mm) of Japanese patients with STEMI. Therefore, the aim of this study was to investigate the clinical outcomes of Japanese patients with STEMI who underwent PCI with DES and BMS implantation in large coronary vessels.
Materials and methods
Written informed consent was obtained from all patients, and data collection for this study was approved by each institution's review board. The Ibaraki Cardiovascular Assessment Study (ICAS) was a multicenter registry involving 12 hospitals in Ibaraki Prefecture, Japan. The present study population consisted of 1100 consecutive patients with STEMI treated with primary PCI at all institutions in the ICAS registry from April 2007 to June 2012 who received a stent. Among these patients, a total of 454 consecutive STEMI patients who were treated with a stent of 3.5 mm or more in diameter were enrolled. Of these 454 patients, we excluded 53 patients classified as Killip class IV or with left main trunk lesion, and thus we examined clinical outcomes of 401 STEMI patients in whom a ≥70% diameter stenosis was present in the epicardial coronary arteries or their major branches by visual estimation. Inclusion criteria for the STEMI patients were (1) chest pain of >30 min in duration and presentation to hospital within 12 h after onset of symptoms; (2) ST-segment elevation of >0.1 mV in two contiguous electrocardiographic leads; and (3) elevated creatine kinase MB isoenzymes within 12 h of chest pain. Among the 401 patients, the BMS group (Group-B) included 217 (54.1%) patients, and the DES group (Group-D) included 184 (45.9%) patients ( Fig. 1 ). Of the 184 patients who received DES, 47.8% of the stents were first-generation DES (SES or paclitaxel-eluting stent), and 52.2% were second-generation DES (zotarolimus-eluting stent, EES, or biolimus-eluting stent). Experienced interventional cardiologists performed coronary angiography through the femoral approach with 6F catheters. The culprit coronary artery was defined on the basis of electrocardiography and angiographic results. All the patients undergoing initial PCI were treated with both aspirin and a 300-mg loading dose of clopidogrel. The contrast agent used was iopamidol (370 mg I/ml; Schering, Berlin, Germany). Postprocedural optimal coronary flow was defined as a Thrombolysis in Myocardial Infarction (TIMI) flow grade of ≥3 and no residual stenosis (less than 10%). Incomplete reperfusion or lack of procedural success was defined as TIMI flow 0-2 [20] . Time to reperfusion was defined as the period from time of onset of symptoms to the time of reperfusion. The standard of care at discharge was to prescribe clopidogrel for 1 year to all patients treated with DES, whereas clopidogrel was prescribed for at least 3 months to patients treated with BMS. All the patients underwent clinical follow-up at 30 days, 6 months, and 1 year as an outpatient, and follow-up angiography was also performed at 6-12 months after PCI.
BMS group
Clinical endpoints were defined as in-hospital death and major adverse cardiac and cerebrovascular events (MACCE). MACCE were defined as all-cause death, MI, TVR, and cerebrovascular accident (CVA). MI was defined as a clinical event with typical electrocardiographic or enzymatic changes [21] . We also investigated the incidence of stent thrombosis, which was defined according to the criteria of the Academic Research Consortium [22] . TVR included all incidences of PCI or coronary artery bypass grafting occurring after the baseline procedure and was diagnosed by recurrent symptoms, reinfarction, or objective report of significant ischemia on provocative testing. Clinical endpoints were documented by clinical visits and standardized follow-up phone calls to the patients or their families, followed by review of medical records. The diagnosis of clinical endpoints was adjudicated by independent cardiologists who were blinded to the findings of this registry. Left ventricular ejection fraction was measured by transthoracic echocardiography in all patients soon after hospitalization.
Continuous variables are presented as mean ± standard deviation (SD) and categorical variables as percentages. Categorical variables were compared between groups using the 2 test or Fisher's exact test when appropriate, whereas continuous variables were compared with an unpaired t-test. Event-free survival curves for cardiac events were constructed using the Kaplan-Meier method, and statistical differences between curves were assessed by the log-rank test. Logistic regression analyses were used to investigate the univariate and multivariate predictors of events during follow-up, adjusting for the differences in baseline patient characteristics, lesion factors, procedural factors, and medications. Multivariate models for MACCE included age and the important variables with p < 0.1 after univariate analysis. Data are presented as hazard ratios and 95% confidence intervals (CI).
Because the patients were not randomly assigned to stent placement, a propensity score analysis was performed by using a logistic regression model for BMS versus DES to adjust for differences in baseline characteristics. The covariates that were adjusted for exposure to stent included age, sex, contrast volume, radiation time, intra-aortic balloon pump (IABP), multivessel disease, transradial intervention, right coronary artery (RCA) lesion, left anterior descending artery (LAD) lesion, Type B2/C, intravascular ultrasound, stent length, peak creatine phosphokinase, warfarin use, renin-angiotensin system inhibitor use, and beta-blocker use. The C-statistic for the logistic regression model that was used to calculate the propensity score matching for the two groups was 0.814. Patients receiving BMS were then 1-to-1 matched to the patients receiving DES on the propensity scores with the nearest available pair-matching method. The maximum difference in the propensity score allowed for a match was 0.013. The procedure yielded 101 well-matched pairs. After propensity score matching, the baseline covariates were compared between the two stent groups. Continuous variables were compared with the paired t test, and categorical variables were compared with chi-square test or Fisher exact test, as appropriate.
All the tests were two-sided, and a p-value of less than 0.05 was considered statistically significant. All the analyses were performed using SPSS software, version 15.0 for Windows (SPSS, Chicago, IL, USA).
Results
We investigated clinical outcomes of 401 STEMI patients who underwent PCI with stent of ≥3.5 mm in diameter. The mean age of patients was 65.2 ± 12.8 years, and 341 (85%) patients were men. Baseline characteristics of the two groups are shown in Table 1 . After a mean follow-up period of 526 days, 14 (3.5%) patients died. There were no differences between the two groups in the incidences of in-hospital death (Group-B vs. Group-D: 1.84% vs. 3.26%; p = 0.37), all-cause death (4.61% vs. 4.35%; p = 0.19), MI (0% vs. 0%), CVA (3.23% vs. 2.72%; p = 0.76), stent thrombosis (1.38% vs. 0%; p = 0.11), and MACCE (20.3% vs. 15.2%; p = 0.19). TVR was lower tendency in Group-D than Group-B (13.4% vs. 8.7%; p = 0.14) ( Table 2 ). Kaplan-Meier analysis showed no significant difference between the two groups in survival free of all-cause death (p = 0.79), or MACCE (p = 0.15). TVR was lower in Group-D than Group-B (p = 0.051) (Figs. [2] [3] [4] .
Compared with patients who underwent PCI with BMS, those who underwent PCI with DES had no significantly increased risk of MACCE [odds ratio (OR): 0.70; 95% CI: 0.41-1.19; p = 0.19] in univariate analysis. Other significant predictors of MACCE in univariate analysis were age, insulin use, multivessel disease, IABP use, RCA culprit, LAD culprit, and estimated glomerular filtration rate <60 ml/min/1.73 m 2 . After adjusting for these seven factors, there were no significant differences in MACCE between the two groups (OR: 0.69; 95% CI: 0.40-1.23; p = 0.21). Independent predictors of MACCE were multivessel disease (OR: 1.88; 95% CI: 1.05-3.37; p = 0.034) and IABP use (OR: 4.58; 95% CI: 1.72-12.1; p < 0.01) ( Table 3) .
After propensity score matching was performed for the entire population, there were 101 matched pairs of patients. Although the two groups were well balanced in baseline characteristics, body mass index and final inflation pressure were higher in Group-D, incidence of peripheral artery disease, prior MI, and graft lesions were higher in Group-D than Group-B (Table 4 ).
There were no differences between the two groups in the incidences of in-hospital death (Group-B vs. Group-D: 1.0% vs. 5.2%; p = 0.10), all-cause death (3.1% vs. 6.2%; p = 0.32), MI (0% vs. 0%), CVA (2.1% vs. 2.1%; p = 1.0), stent thrombosis (1.0% vs. 0%; p = 0.32), and MACCE (19.6% vs. 16.5%; p = 0.55). TVR was lower tendency in Group-D than Group-B (15.5% vs. 8.2%; p = 0.09) ( Table 5 ). Kaplan-Meier analysis showed no significant difference between the two groups in survival free of all-cause death (p = 0.13), or MACCE (p = 0.27). TVR was lower in Group-D than Group-B (p = 0.049) ( Figs. 5-7) .
We also investigated possible differences between firstgeneration DES (SES or paclitaxel-eluting stent: n = 88) and secondgeneration DES (zotarolimus-eluting stent, EES, or biolimus-eluting stent: n = 96). There were no differences between the two groups in the incidences of in-hospital death (first-generation DES vs. second generation DES: 2.30% vs. 4.17%; p = 0.37), all-cause death (5.75% vs. 3.13%; p = 0.39), MI (0% vs. 0%), CVA (2.30% vs. 3.13%; p = 0.73), stent thrombosis (0% vs. 0%), and MACCE (20.7% vs. 10.4%; p = 0.054). However, the incidence of TVR was significantly lower in the second-generation DES group (4.17%) than in the first-generation DES group (13.8%) (p = 0.021). 
Discussion
The main finding of the present study of patients with STEMI requiring large coronary stents (≥3.5 mm) was that during the median follow-up period, all-cause death, MI, CVA, MACCE, and ST were not significantly different between patients receiving BMS and those receiving DES. However, DES might have a benefit for preventing TVR. The likelihood of a benefit from DES is relatively small in patients with occlusions in large coronary arteries because the rate of restenosis is low and the risk of adverse cardiac events due to late stent thrombosis may be greater than the risk among patients with small-vessel stents [6, 7, 23] . Steinberg et al. reported that implantation of DES in large coronary arteries confers no additional benefit compared with BMS, and the two approaches are associated with equally favorable clinical outcomes at 1 year [18] . We also could not prove an advantage of DES over BMS in large coronary arteries for preventing hard endpoints in the STEMI setting.
Although Shugman et al. reported that BMS deployment in STEMI patients with infarct-related arteries of ≥3.5 mm in diameter was associated with low rates of TVR [24] , we reported the benefit of DES for preventing TVR. This report showed an incidence of death at 1 year of 4.4%, which is similar to our result (4.6%). However, the incidence of TVR was 2.2% in their report, whereas it was 13.4% in the present study. This might be related to the inclusion of relatively large numbers of patients at high risk for events from an all-inclusive clinical setting rather than a randomized controlled trial. Also, follow-up was longer in our study than in previous studies. Recently, a comprehensive network meta-analysis that included 22 trials with 12,453 STEMI patients demonstrated that EES were associated with significantly lower rates of 1-year cardiac death/MI, MI, definite stent thrombosis, and definite/probable stent thrombosis than were BMS, and the reduction in cardiac death/MI and in stent thrombosis with EES compared to BMS was already apparent at 30 days and was maintained for up to 2 years of follow-up [25] . Sabate et al. reported that the use of EES compared with BMS in the setting of STEMI did not lower the patient-oriented endpoints, but at the stent level, rates of both target lesion revascularization and stent thrombosis were reduced [26] . However, these studies did not show an additional benefit of DES use in large coronary arteries compared with BMS. It is important to note that our study indicated the usefulness of BMS in the STEMI setting with large coronary arteries. Discontinuation of dualantiplatelet therapy might be a relief for the patients receiving BMS, for whom their medical background, such as the presence of malignancy or a bleeding disorder, is unknown in the emergency setting at the time of STEMI. Gomez et al. reported in their sub-analysis of the EXAMINATION study that patients with STEMI and proximal LAD lesions treated with EES have better outcomes than those treated with BMS at 1 year [27] . We also investigated lesion sites, but there was no significant difference in MACCE for LAD lesions (Group D vs. Group B: [28] . Our study suggests that the incidence of stent thrombosis was low in patients with large vessels in both groups, but additional follow-up would be needed to further investigate late-term events.
We also compared first-generation DES with second-generation DES. There were no differences in the incidences of in-hospital death, all-cause death, MI, CVA, stent thrombosis, and MACCE between the first-generation and second-generation groups. However, the incidence of TVR was lower in the second-generation group than in the first-generation group. Although we could not prove an advantage of second-generation DES over that of the firstgeneration DES in terms of MACCE, there was a trend toward a more favorable outcome with the second-generation DES. This result might be influenced by lack of required number of patients, and therefore, additional follow-up will be needed in a larger population.
Several limitations in the design of the ICAS registry should be mentioned. This retrospective, nonrandomized study included a relatively small sample size. In observational studies, outcomes may reflect a lack of comparability in treatment groups rather than the effects of treatment. All the components of the primary endpoints, including in-hospital death and MACCE, are less subject to observation bias. The rates of use of statins and beta-blockers were low in the registry, unlike that in current practice. Finally, it should be noted that the findings of this study do not relate to patients with smaller coronary arteries.
